Nasdaq:ORIC

<!-- Name:DistributionId Value:8787487 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance,…

ORIC-533 oral presentation and poster presentation to highlight potential of small molecule inhibitor of CD73 as a treatment for multiple myeloma ORIC-114 poster presentation to highlight compelling brain penetrant properties of an…

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance,…

CD73 inhibition overcomes immunosuppression and demonstrates activity in assays derived from relapsed or refractory multiple myeloma patients, offering the potential for single agent activity in the clinic Phase 1 trial of single agent…

Call to discuss poster presentation on ORIC CD73 inhibitor in human ex vivo multiple myeloma systems presented at the American Society of Hematology (ASH) Annual Meeting Senior author Dr. Kenneth Anderson to discuss beneficial effects of…

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance,…

SOUTH SAN FRANCISCO and SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today…